Pancreatic Cancer Research

ResearcherUniversity of GroningenActive in the last 2 years

Maarten W. Nijkamp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5074-2032; OpenAlex author ID A5018448894. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 6 papers · 2025: 4 papers · 2026: 3 papers

Papers 15

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  5. Preoperative Anemia as a Prognostic Risk Factor for Inferior Oncological Survival Following Resection for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002448↗
  6. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  7. It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fimmu.2025.1495907↗
  8. Nutritional support in pancreatic cancer patients and its effect on nutritional status: an observational regional HPB network study investigating current pract… Co-author DOI 10.1007/s00520-024-08683-0↗
  9. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  10. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  11. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  12. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  13. Association Between Physical Activity and Pancreatic Cancer Risk and Mortality: A Systematic Review and Meta-Analysis. Last author DOI 10.3390/cancers16213594↗
  14. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Co-author DOI 10.1002/jso.26670↗
  15. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Co-author DOI 10.1002/bjs.11093↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Maximilian Bockhorn · 3 shared papers, 2024–2025 · strength 0.75
  2. N. Helge Meyer · 3 shared papers, 2024–2025 · strength 0.75
  3. Joost M. Klaase · 4 shared papers, 2024–2025 · strength 0.71
  4. Marcel den Dulk · 5 shared papers, 2019–2026 · strength 0.67
  5. Nabiha Akhlaq Mughal · 3 shared papers, 2024–2026 · strength 0.48
  6. Thijs J. Schouten · 3 shared papers, 2024–2026 · strength 0.48
  7. Freek D. Daams · 3 shared papers, 2024–2026 · strength 0.48
  8. Omar Mahmud · 3 shared papers, 2024–2026 · strength 0.48
  9. Gijs A. Patijn · 3 shared papers, 2024–2026 · strength 0.48
  10. Lois A. Daamen · 3 shared papers, 2024–2026 · strength 0.48
  11. Ingmar Florin Rompen · 3 shared papers, 2024–2026 · strength 0.48
  12. Izaak Quintus Molenaar · 3 shared papers, 2024–2026 · strength 0.48
  13. Kelly J. Lafaro · 3 shared papers, 2024–2026 · strength 0.48
  14. Sebastiaan Festen · 3 shared papers, 2024–2026 · strength 0.48
  15. Richard Andrew Burkhart · 3 shared papers, 2024–2026 · strength 0.48
  16. Bas Groot Koerkamp · 3 shared papers, 2024–2026 · strength 0.48
  17. Thomas F. Stoop · 3 shared papers, 2024–2026 · strength 0.48
  18. Joseph R. Habib · 3 shared papers, 2024–2026 · strength 0.48
  19. Ignace H. J. T. de Hingh · 3 shared papers, 2024–2026 · strength 0.48
  20. Iris W.J.M. van Goor · 3 shared papers, 2024–2026 · strength 0.48
  21. Paul C. M. Andel · 3 shared papers, 2024–2026 · strength 0.48
  22. Hjalmar C. van Santvoort · 3 shared papers, 2024–2026 · strength 0.48
  23. Christopher Lee Wolfgang · 3 shared papers, 2024–2026 · strength 0.48
  24. Marc G. Besselink · 3 shared papers, 2024–2026 · strength 0.48
  25. J. Sven D. Mieog · 3 shared papers, 2024–2026 · strength 0.48

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.